COEPHIGH SIGNALFINANCIAL10-K

COEP shows dramatic balance sheet improvement with 650% debt increase alongside massive equity growth, but deteriorating operations with 30% worse operating losses.

The company appears to have completed a significant financing round, dramatically strengthening its balance sheet with $10.4M more stockholders' equity and substantially improving its liquidity position by reducing current liabilities 61%. However, the worsening operating losses despite reduced R&D spending suggests fundamental operational challenges that could accelerate cash burn despite the stronger financial position.

Comparing 2026-03-19 vs 2025-03-28View on EDGAR →
FINANCIAL ANALYSIS

COEP underwent a major financial transformation with current assets surging 599% and stockholders' equity growing $10.4M, while simultaneously reducing total liabilities by 59% and cutting current liabilities from $4.5M to $1.8M. Operating performance deteriorated significantly with losses widening 30% to $13.0M despite a 45% reduction in R&D expenses, suggesting operational inefficiencies beyond development costs. The combination of dramatically improved balance sheet strength offset by worsening operational performance creates a mixed but notable financial picture requiring close monitoring of cash burn rates.

FINANCIAL STATEMENT CHANGES
Total Debt
Balance Sheet
+650%
$150K$1.1M

Debt increased 650% — substantial leverage increase; assess whether deployed for growth or covering losses.

Current Assets
Balance Sheet
+599.2%
$1.1M$7.4M

Current assets grew 599.2% — improving short-term liquidity or inventory/receivables build.

Stockholders Equity
Balance Sheet
+325.8%
$3.2M$13.6M

Equity base grew 325.8% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Total Assets
Balance Sheet
+81.3%
$8.9M$16.2M

Asset base grew 81.3% — expansion through organic growth, acquisitions, or capital deployment.

Current Liabilities
Balance Sheet
-60.8%
$4.5M$1.8M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Liabilities
Balance Sheet
-58.6%
$5.0M$2.1M

Liabilities reduced 58.6% — deleveraging improves balance sheet strength and financial flexibility.

Cash & Equivalents
Balance Sheet
-55.4%
$907K$404K

Cash declined 55.4% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Interest Expense
P&L
-50.7%
$218K$108K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

R&D Expense
P&L
-45.2%
$2.3M$1.3M

R&D spending cut 45.2% — could signal cost discipline or concerning reduction in innovation investment.

Operating Income
P&L
-29.7%
-$10.1M-$13.0M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

LANGUAGE CHANGES
NEW — 2026-03-19
PRIOR — 2025-03-28
ADDED
Management s Discussion and Analysis of Financial Condition and Results of Operations 32 7A.
This report includes our audited consolidated financial statements as of and for the years ended December 31, 2025 and December 31, 2024.
The biopharmaceutical division focuses on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases.
Coeptis aims to advance treatment paradigms and improve patient outcomes through its cutting-edge research and development efforts.
The technology division focuses on enhancing operational capabilities through advanced technologies.
+7 more — sign up free →
REMOVED
Management s Discussion and Analysis of Financial Condition and Results of Operations 33 7A.
This report includes our audited consolidated financial statements as of and for the year ended December 31, 2024.
This report also includes our audited consolidated financial statements as of and for the year ended December 31, 2023.
Our current business model is designed around furthering the development of our current product portfolio.
Our biopharmaceutical division is continually exploring partnership opportunities with companies that have novel therapies in various stages of development or companies with technologies that improve the way that drugs are delivered to patients.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →